Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Eli Lilly Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (71)
Cancellation by sponsor (69)
Australian Public Assessment Report (AusPAR) (21)
Prescription medicine registration (21)
Designation or determination (4)
Prescription medicine decision summary (4)
Prescription medicine evaluation (4)

Date

2026 (9)
2025 (28)
2024 (21)
2023 (21)
2022 (15)
2021 (10)
2020 (4)
2019 (34)
2018 (14)
2017 (1)
2016 (2)
2015 (5)
2014 (2)
2013 (4)
2012 (1)
2011 (2)
2010 (1)
2008 (2)
2007 (1)
2006 (1)
2004 (1)
2002 (2)
1999 (4)
1998 (1)
1996 (2)
1992 (4)
1991 (2)

Search

Sponsor content

194 result(s) found, displaying 141 to 150

OLANZAPINE LY olanzapine 5mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
OLANZAPINE LY olanzapine 7.5mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
EMGALITY (Eli Lilly Australia Pty Ltd)

22 May 2019

Prescription medicine registration

Active ingredients: galcenezumab.
VERZENIO (Eli Lilly Australia Pty Ltd)

8 April 2019

Prescription medicine registration

Active ingredients: abemaciclib.
AXIRON testosterone 2% w/v solution bottle Cancelled under Section 30(1)(c) of the Act

5 March 2019

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
AusPAR: Ixekizumab

15 January 2019

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Ixekizumab
HUMALOG U200 KwikPen insulin lispro (rbe) 200 IU/mL solution for injection multidose syringe (226893)

9 November 2015

ARTG

Australian Register of Therapeutic Goods (ARTG) information for HUMALOG U200 KwikPen insulin lispro (rbe) 200 IU/mL solution for injection multidose syringe.
HUMALOG NPL insulin lispro 100U/mL injection multidose cartridge Cancelled under Section 30(1)(c) of the Act

29 June 2018

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
HUMALOG NPL KwikPen insulin lispro 100U/mL injection multidose syringe Cancelled under Section 30(1)(c) of the Act

29 June 2018

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd
TRENUVIS pemetrexed (as disodium) 100 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

29 June 2018

Cancellation by sponsor

Requested by Eli Lilly Australia Pty Ltd

Pages

First page
Previous page
…
Page 11
Page 12
Page 13
Page 14
Current page 15
Page 16
Page 17
Page 18
Page 19
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.